Journal section: Oral Medicine and Pathology Publication Types: Review doi:10.4317/jced.59348 https://doi.org/10.4317/jced.59348

The Effect of Photodynamic Therapy on Oral-Premalignant Lesions: A Systematic Review

Ruchika Choudhary¹, Sujatha S. Reddy², Ravleen Nagi³, Rakesh Nagaraju⁴, Sreekanth P. Kunjumon⁵, Ritu Sen⁶

¹Assistant Professor. Department of Oral Medicine and Radiology, NIMS Dental College and Hospital, Jaipur, Rajasthan

² Professor. Department of Oral Medicine and Radiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, MSRIT post Mathikere, 560054, Bangalore, India

³ Reader. Department of Oral Medicine and Radiology, Saveetha Dental College, 600077, Chennai, Tamil Nadu

⁴ Professor and Head. Department of Oral Medicine and Radiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, MSRIT post Mathikere, 560054, Bangalore, India

⁵ Post Graduate Student. Department of Oral Medicine and Radiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, MSRIT post Mathikere, 560054, Bangalore, India

⁶ Post Graduate Student. Department of Oral Medicine and Radiology, Faculty of Dental Sciences, MS Ramaiah University of Applied Sciences, MSRIT post Mathikere, 560054, Bangalore, India

Correspondence: NIMS Dental College and Hospital Jaipur, Rajasthan, 303121 drruchikac@gmail.com

Received: 02/01/2022 Accepted: 06/02/2022 Choudhary R, Reddy SS, Nagi R, Nagaraju R, Kunjumon SP, Sen R. The effect of photodynamic therapy for oral-premalignant lesions: A systematic review. J Clin Exp Dent. 2022;14(3):e285-92.

l	Article Number: 59348 http://	/www.medicinaoral.com/odo/indice.htm
l	© Medicina Oral S. L. C.I.F. B 96689.	336 - eISSN: 1989-5488
l	eMail: jced@jced.es	
l	Indexed in:	
l	Pubmed	
l	Pubmed Central® (PMC)	
l	Scopus	
l	DOI® System	

Abstract

Background: Dentists now have access to a wide range of unique treatment methods as a result of substantial scientific and technological breakthroughs in the field of dentistry. Photodynamic therapy (PDT) is a non-invasive treatment procedure that use photosensitizers, a specific wavelength of light, and the production of singlet oxygen and reactive oxygen species (ROS) to kill undesired eukaryotic cells (such as oral tumors) and harmful microbes. In several disciplines of dentistry, it is seen as a valid therapeutic option. The purpose of this study was to examine the effectiveness and side effects of PDT in the treatment of oral premalignant lesions.

Material and Methods: Three search engines (PubMed, ISI Web of Science, and the Cochrane Library) were used to conduct a systematic review using the phrases photodynamic therapy and PDT in combination with other terms. To define our study eligibility criteria, we used the Population, Intervention and Comparison, Outcomes, and Study design technique.

Results: Initial results were 33. Definitely, 18 studies met our selection criteria.

Conclusions: Our analysis suggests ALA- PDT as a promising therapeutic modality for OEL lesions which should be treated first with the topical ALA-PDT using either the LED or laser light for successful clinical outcome for OEL lesions.

Key words: Photodynamic Therapy, Photosensitizer, Aminolevulinic Acid (ALA), Methylene Blue (MB), Toludine Blue, Oral Leukoplakia, Oral Erythroplakia, Oral Verrucous hyperplasia, Oral Lichen Planus.

Introduction

A variety of therapeutic approaches have been proposed for the treatment of oral per-malignant lesions (such as leukoplakia [OL], oral erythroplakia [OE], oral verrucous hyperplasia [OVH] and oral lichen planus [OLP]). Some of the treatment options include topical medication (such as vitamin A, antibiotics, and steroids), LASER ablation, cryotherapy, and surgical excision. Non-surgical treatment approaches for pre-malignant lesions (such as topical medication delivery) may be beneficial in the short term, but they have been linked to high recurrence rates. Furthermore, it has been demonstrated that surgical treatment of oral precancerous lesions increases morbidity and scar tissue development.

For the treatment of premalignant lesions in the mouth, photodynamic therapy (PDT) is a novel treatment option. PDT includes the interaction of a light source with a chemical dye or photosensitizer in the presence of oxygen (PS). As a result of this interaction, reactive oxygen species are formed, causing oxidative damage to microbial cell walls as well as pre-malignant and malignant cells. Oscar Raab discovered in 1900 that paramecia was destroyed by the interaction of acridine (a dye) and visible light in the presence of oxygen [32]. Later, Niels Finsen undertook research on the use of the arc light in phototherapy, for which he was awarded the Nobel Prize in 1903 [32]. Professor Hermann von Tappeiner, head of the Pharmacological Institute of the Ludwig-Maximilians University in Munich [33], coined the phrase 'photodynamic action' ('photodynamische Wirkung') in 1904. In 1913, the German physician Friedrich Meyer-Betz conducted the first investigation with porphyrins, which was first dubbed photo radiation therapy (PRT). On his own skin, he evaluated the effects of hematoporphyrin-PRT. With early clinical argon dye LASER, John Toth, as product manager for Cooper Medical Devices Corp, Cooper Lasersonics, recognised the photodynamic chemical impact of the therapy and authored the first white paper renaming the therapy as Photodynamic Therapy (PDT). This was done to help fund the establishment of ten clinical locations in Japan, where the word radiation was associated with negative connotations [32]. The University of Berlin's Auler and Banzer identified the characteristic red fluorescence of porphyrins in mouse tumours in 1942. This discovery marked the start of the field of photodynamic diagnostics (PDD).

PDT was used to treat 10 individuals with oral lichen planus (OLP) in a research by Rakesh *et al.* (1). The results demonstrated that OLP was completely eradicated, with no recurrence during a four-year follow-up period. Mirza reported similar findings. S *et al.* (17). According to the findings of these studies, PDT may be a potential therapy approach for the management of oral premalignant lesions (1-17). PDT treatment for oral premalignant lesions, however, resulted in recurrence and secondary infection in three individuals after six months, according to research (16). In this context, there appears to be considerable disagreement over the effectiveness of PDT in the treatment of oral premalignant lesions. The goal of this study was to look at the efficacy and side effects of PDT in the treatment of oral premalignant lesions in a systematic way.

Material and Methods

-Focused Questions

1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria were utilised to construct a focused query. The following was the question that was addressed: -

2. Is PDT useful in the treatment of premalignant lesions in the oral cavity?

3. Which are the photosensitizer most commonly used?4. Is PDT cause any adverse effect during or post-treatment?

5. Follow-up and Recurrence Rate?

-Eligibility Criteria

The following requirements had to be met:

Original investigations, clinical studies, case reports, and intervention studies were all required. -the efficacy of PDT in the treatment of oral premalignant lesions, and works written solely in English.


Review papers, experimental research, letters to the editor, and unpublished works were not taken into account. Search Strategy

In PubMed/Medline (National Library of Medicine, Bethesda, Maryland), Google Scholar, EMBASE, and the ISI Web of Knowledge database, the following keywords were searched from 2000 to 2020: Oral premalignant lesions, oral lichen planus, and photodynamic treatment are all conditions that can be treated using photodynamic therapy. The writers reviewed and double-checked the titles and abstracts of articles that satisfied the qualifying requirements. The entire texts of eligible articles were checked and independently appraised using the title and abstract eligibility criteria. Following that, the authors discussed and agreed on the reference lists of original and review studies that they thought were significant (Fig. 1). In the initial search, 33 studies were discovered. In total, 17 studies (1,2,4,5,8-13,15-17,23,24,26,28) were included and data was extracted from them. The current study's design was tailored to primarily summarize the important data.

Results

-General characteristics of the studies

Pre-existing oral premalignant lesions with or without dysplasia that were clinically and histopathologically identified were included in all investigations (1,2,4,5,8-13,15-17,23,24,26,28). OL, OEL, OLP, and OVH were



Literature search according to PRISMA Guidelines

Fig. 1:

seen in all premalignant lesions treated in all studies (1,2,4,5,8-13,15-17,23,24,26,28). 297 instances of premalignant lesions were documented in this study (1,2,4,5,8-13,15-17,23,24,26,28). The buccal and labial mucosa (maxilla and mandible), tongue, palate, floor of the mouth, bucco-gingival sulcus, and concomitant gingiva were characterized in fifteen investigations (1,4,5,8-13,15-17,23,24,26,28).

In a study by Koty Naik *et al.*, the effectiveness of PDT was compared to that of conventional treatment (control group) in the management of premalignant lesions (12). (The OL and OLP acronyms stand for old and new and old In the research, PDT was compared to LLT and topical corticosteroids (17). Chuan *et al.* conducted a clinical evaluation of OLE and PDT utilising either light-emitting diode or laser light (26).

-Included research' LASER-related parameters

Diode LASERS, light emitting diode (LED), and dye LASERS were used in teen (1,2,5,12,13,15,16,17,26,28), three (4,8,10) and two (24,11) studies, respectively. Diode LASER (24,11), argon pumped dye (24) and pulsed dye LASER (11) were used in these research. In one research (23) xenon arch lamp light was used. All of the studies used LASERS with wavelengths, energy fluences, and power densities ranging from 480 to 670 nanometers (nm), 6 to 200 joules per square centimetre (J/ cm²), and 100 to 150 milliwatts per square centimetre

 (mW/cm^2) (1,2,4,5,8-13,15-17,23,24,26,28). Thirteen studies (1,4,5,9-13,16,17,23,24,26,28) reported a number of sessions ranging from one to twelve, (Table 1, 1 cont., 1 cont.-1.).

Discussion

In 2020, Dario et al. [10] treated 11 OL with PDT; the reported result revealed that 40% of the lesion had a complete response(CR), and 46.7% reported a partial response(PR), while in 13.4% no response(NR) at the end of the treatment and most commonly involved site was the adherent gingiva. In 2007, Chen et.al., treated 32 OL lesions with topical ALA with PDT; the reported results revealed that 1/3 of the 32 OL lesion could achieve a CR after treatment twice a week. Even after 10 months of treatment, 94 percent (16/17) of PR or NR OL lesions were challenging to attain a CR. During the follow-up period, 7.8% (28/36) of the follow-up OL lesions showed a small increase in the size of the residual lesion [8]. In 2006, Aghahosseini et al., reported 5 OLP lesion, treated with MB mediated PDT. Two lesions completely resolve (CR). A PR (more than 50% improvement) was observed in TWO other lesions. There was no recurrence in improved lesions after 9 months follow-up. But no improvement was observed in lesion on the tongue [16]. In study, Umber et al. (2014), lesion showed CR after 4 session of PDT and no recurrence was noted after 12 mon-

S.NO	Author	Year of Publication	Lesion	Cases and Control	Photoactivator drug	Photoactivator light tool and protocol timing	Follow –up	Side effect
-	Aleksandar Sieron et al. (24)	2003	ТО	12	10% ALA	No. of session; - 6-8, Irradiated was performed in several sessions using light from an argon- pumped dye LASER at 635nm wavelength, delivering a total dose of 100j/cm2 per session. 10-20% margin around lesions in the field of irradiation also included. The treatment time – 15min at low fluence rate & was interrupted periodically to prevent excessive photo- sensitizer bleaching		 One recurrence was observed during 6 months Moderate pain dur- ing treatment, localized erythema and oedema were observed immediately after light exposure. 30% patients had an acute pain PDT associate with secondary infection in 3 patients
7	Soliman et al. (2)	2005	OLP	25		Diode LASER is calibrated and measured to the desired power. The irradiated lesion area was selected by the aid of aiming pilot laser beam then was irradiated by 8-watt diode LASER. The lesion was irradiated until the area changed to white color i.e. photocoagulation was completed	6 months	Recurrence that occurred after three months in 1 case and four months in 2 cases
3	Farzane Aghahosseini et al. (16)	2006	OLP	2	Methlene Blue(MB)	No. of session; - 3 (3,7,15 days) A diode LASER (632nm, CW) was used as light source. The lesion and 1cm of their surrounding marginal zone were illumi- nated with a spot size of 2.5 – 3cm ² . Large lesion were illuminated with multiple spots. A fluence of 100j/ cm2 was used.	9 Month	No side effects
4	Chuan-Hang Yu et al. (8)	2007	НЛО	36	20% ALA	Irradiated with an LED red light at 635+/- 5mm sepa- rated by five 3min rests for a total of 1000s (fluence rate, 100mW/cm2, light exposure dose, 100j/cm ²) 1.5 – 2h after topical application of 20%ALA onto oral lesions		No side effects
S	Chuan-hang Yu et al. (26)	2009	OEL	46	20% ALA	No. of sessions: once a week till the lesion is com- pletely gone. For a total of 1,000 seconds, the lesion was irradiated with either an LED red light at 635 +/- 5nm or a 635nm laser light (fluence rate, 100nW/cm2; light exposure dosage, 100j/cm ³). The 1000-second treatment was split into five 3-minute sessions and one 100-second irradiation session separated by five 3-minute sessions.		During PDT, 35 OEL with severe throbbing pain or a burning sensation received light therapy under local anaesthetic with 2% lidno- caine.

Both OVH & OEL lesions was irradiated with a 635nm LASER light generated by the Art-LASER Power-adjustable (from 0 to 1200nm) diode LASER. (Fluence rate-100nW/cm2, light exposure dose, 100j/cm2). The 1000s-treatment period was divided into five 3-min rests.	No. of session; -8(separated by 6 to 8 week). A PDL that emits (pulsed dye LASER) light with a 585nm wavelength in pulses of1-5ms at intervals of 1 to 3 sec.	5% Methylene Blue No. of session; -4(1,4,7,15 day). Lesion with 1cm sur- rounding marginal zone was illuminated with xenon arch lamp light at wavelength of 632 +/- 5nm for 20 min rotal door dates dates are 100,502 for one of
20%ALA	5ALA	5% Methylene Blue
40 (OVH) & 40 (OEL)	23	20
Oral Ver- rucous Hy- perplasia and Oral Erythro- plakia	ТО	OLP
2010	2011	2012
Hung pin Lin et al. (15)	Gal Shafirstein et al. (11)	Jaya Chandran et al. (23)

Table 1: 1 cont.

				-				
9	Hung pin Lin et al. (15)	2010	Oral Ver- rucous Hy- perplasia and Oral Erythro- plakia	40 (OVH) & 40 (OEL)	20%ALA	Both OVH & OEL lesions was irradiated with a 635nm LASER light generated by the Art-LASER Power-adjustable (from 0 to 1200nm) diode LASER. (Fluence rate-100nW/cm2, light exposure dose, 100j/ cm2). The 1000s-treatment period was divided into five 3-min rests.		Initially sever throbbing pain and marked burning sensation notice.
٢	Gal Shafirstein et al. (11)	2011	TO	23	SALA	No. of session; -8(separated by 6 to 8 week). A PDL that emits (pulsed dye LASER) light with a 585mm wavelength in pulses of1-5ms at intervals of 1 to 3 sec.	365 days	Sensitivity, soreness, swell- ing, burning feeling, taste modification, and ulceration were among the minor side effects experienced after therapy.
∞	Jaya Chandran et al. (23)	2012	OLP	20	5% Methylene Blue	No. of session; $-4(1,4,7,15 \text{ day})$. Lesion with 1cm surrounding marginal zone was illuminated with xenon arch lamp light at wavelength of 632 \pm /- 5nm for 20 min. total dose delivered was 120j/cm ² for each sitting.	2 nd & 4 th week after therapy	No side effects
6	Sigrid et al. (31)	2013	OLP	14 cases	MAL-PDT	The light exposure was done three hours after the MAL cream was initially applied. Using a light- emitting diode (LED) light source, a radiant exposure of 75 J/cm2 of red light in the range 600 to 660 nm was provided at irradiances of 100 to 130 mW/cm ² . Four high-power LEDs (Luxeon I Emitter, Lumileds, San Jose, CA) were used to deliver light via a 2-cm acrylic guide.	30 months	No side effect
10	Umberto Ro- meo et al. (5)	2014	OPVL	1	20% Gel SALA	No. of session; - 4, Diode LASER used with 635nm wavelength. Each application consists of five 3 min and one 1008 irradiations with five 3 minutes breaks for a total of 1000s (fluence rate: - 100mW/cm2, total energy dose 100j/cm ²) with fractionated protocol.		No side effects
=	Hsin Ming Chen et al. (4)	2015	OEL	20	5ALA	No. of session; - once in a week for 6 months, irradi- ated with 635nm by LED light		No side effect
12	Kotya Naik et al. (12)	2016	OL & OLP	21	98% 5ALA	No. of session-12, Irradiated by light emitting diode(LED) blue light with a wavelength of 480nm and intensity >500mW/cm ²	Not mentioned	No side effect
13	Shivani Shar- ma et al. (28)	2017	Erosive OLP	1	5-ALA	No. of session; -1, Irradiated by red diode LASER 660nm.	6 months	No side effects
14	Sana Mirza et al. (17)	2018	Erosive- atrophic OLP	15	Toluidine Blue 50 μl topical application	No. of session; - 2(2 times weekly). Irradiation by GaAIAs LASER with wavelength of 630nm, 10mW/ cm2, continuous wave, spot size; -1cm ²	1 year	No side effects

Table 1	Table 1: 1 cont1							
15	N. Rakesh (1)	2018	OLP	10 cases	ALA gel 4% (4mg) (2mg at each appli- cation)	No. of session; 1. Irradiated by red light emitted by Diode LASER of wavelength of 600-670nm, energy density of 80j/cm ² via brushing motion of optical fiber tip of diameter 320nm	4 years	No significant adverse ef- fects
16	Fatemeh et al. (13)	2019	TO	8 cases	Toluidine Blue	Number of session; -3 (1, 7 & 14 Day), Irradiated with a 660nm diode LASER In GaAIP for 10min with spot technique, Power; - 20mW. The Fluence was 19.23j/ cm2, probe cross section was 0.78cm2		No side effect
17	Dario Di stasio et al. (10)	2020	TO	11 cases	2.5% Toludine Blue	2.5% Toludine Blue 2-12 Irradiation using a 630nm LED source in a circular motion for 4 minutes and 30 seconds, with a power range of 7.2 to 14.4 j/cm2. A microlens is a fiberoptic cable that has been terminated in a microlens.		No side effect

ths [5]. Koty Naik et al. (2016) studied 13 patients with 24 OL lesions and 8 patients with 29 OLP lesions who were treated with PDT (study group) and conventional therapy (control group). According to the distribution of OL and OLP lesions for PDT, 9 (75.0%) lesions were on the BM, 2 (16.66%) on the tongue, and 1 (8.33%) lesion on the associated gingiva in OL, and 9 (90.0%) lesions were on the buccal mucosa, 1 (10.0%) lesion on the attached gingiva in LP. Although 10 (83.33%) lesions were on the BM, 1 (8.33%) lesion on the tongue, and 1 (8.33%) lesion on the gingiva in conventional therapy, in OLP, 6 (60.0%) lesions were on the BM, 2 (20.0%) on the connected gingiva, and 2 (20.0%) on the tongue. In the OLP PDT group, two (16.66 percent) of the 12 lesions were CR, eight (66.66 percent) were PR, and two (16.66 percent) were NR. Twelve lesions were found in the conventional group, with two (16.66%) indicating PR and nine (75.0%) showing NR. Twelve lesions were found in the conventional group, with two (16.66%) indicating PR and nine (75.0%) showing NR. In OLP with PDT, 8 (80.0%) of the 10 lesions diagnosed had PR and 2 (20.0%) had NR, whereas in conventional treatment, 10 lesions were found, with 8 (80.0%) having PR and 2 (20.0%) having NR [16].

In 2007, Chen et.al; treated 24 OVH lesions, 65 OL lesions and 6 OEL lesions with topical ALA-PDT once a week and 32 OL lesions were treated with ALA-PDT twice a week. After 1-6 treatments, all 24 OVH lesions showed CR, while 65 OL lesions showed CR in 5, PR in 33, and NR in 27. In the 32 OL lesions treated twice a week with ALA PDT, 11 showed CR and 21 showed PR. The clinical result of the 32 OL lesions treated twice a week was significantly better than the 65 OL lesions treated once a week. According to this study, CR of an OVH lesion can be accomplished in as little as seven treatments in a week. OL lesions treated twice a week have a significant better clinical outcome than OL lesions treated once a week. OEL lesions treated once a week have a significantly better clinical outcome than OL lesions treated once a week [8]. In 2011, Galll Shafirstein et al.; reported 23 patients of OL aged between 37 to 79 years, treated with 5-ALA and pulsed dye laser, noted that more than 75% resolution of the lesion; PR, reduction of at least 25% and NR, reduction by less than 25% [11]. In a study reported in 2019, Fatemeh et al.; treated 11 patient of OLP lesion by comparing the effect of PDT (toludine blue) and topical corticosteroid (0.1%)triamcinolone acetonide). PDT alone and in comparison with the control side without any interventional up to session 3/day 21 was significantly more effective, but by starting the topical corticosteroid therapy for both side of the intervention and control, this discrepancy was compensated by 4-week application of topical corticosteroid. Author state that PDT can reduce the treatment session, while topical corticosteroids application may need to be continued for several weeks. Also, PDT can be used as an adjuvant therapy in combination with topical steroid for resistant or recurrent OLP [13]. Hung Pin et al. (2010) reported 40 OVH and 40 OEL treated with ALA-PDT, finding that all 40 OEL lesions displayed CR after an average of 3.6 PDT therapy, with 38 showing CR and 2 showing PR after an average of 3.4 PDT treatment [13]. In 2018, study Mirza Sana et al.; reported 25 OLP lesion on the tongue or buccal mucosa treated with toluidine blue PDT, LLT and topical corticosteroids application, they indicated that PDT and LLT both are effective in treatment of Erosive-atrophic form OLP. However, PDT showed superior results than LLT, while corticosteroid application reduced significantly greater pain as compared to both PDT and LLLT groups [17]. In 2018 study, Rakesh et al.; treated 10 patient Erosive OLP between the age group of 20-70 with ALA-PDT, reported excellent result in 1 session with remarkable reduction in sign and symptoms, although post-inflammatory hyperpigmentation persisted and no recurrence in 4 year follow-up [1]. Similarly Shivani et al. (2017)., treated Erosive OLP with ALA -PDT, showed excellent result in 1 session with no recurrence in 6 month follow-up [28]. Sadaksharam et al. (2012) reported 20 patients OLP treated with 5% Methylene Blue mediated PDT (xenon arc Lamp), noted that no improvement in 3 cases; moderate improvement in 9 cases; marked improvement in 6 cases and CR in two cases. Aleksander Sieron et al. (2003), reported a study, 12 patient with OL treated with 10%ALA using PDT (argon-pumped dye LASER). Out of 12 Patient, 10 showed CR, 2 - NR and 1 recurrence was observed during 6 months [24]. Yu-Chuan et al. (2009) investigated 46 OEL cases, 20 of which were treated with ALA-PDT using LED light and 26 of which were treated with ALA-PDT using LASER light of the same wavelength (635), and found that the 20 LED light-treated OEL lesions exhibited CR in 17 instances and PR in three cases. CR was found in 25 of the 26 laser-light-treated OELs, whereas PR was found in one [26]. Sigrid et al. (2013) described 14 instances of OLP where one side was treated with MAL-PDT and the other was not. All of the participants in the experiment had improved after three months. Two patients had relapsed by the 6-month follow-up, although new lesions were only found in areas where amalgam fillings were in direct contact. These patients were subsequently advised to have their fillings replaced, and as a consequence, the mucosa healed completely.

Conclusions

Our findings point to ALA-PDT as a viable treatment option for dysplastic OEL lesions, which should be treated initially with topical ALA-PDT using either LED or laser light for a positive clinical result. Furthermore, topical ALA-PDT is a minimally invasive approach that may be utilized to treat recurring or resistant lesions on a regular basis without creating major short- or long-term negative effects. However, because there is insufficient evidence to support ALA-PDT as a first-line treatment for dysplastic OEL lesions, more longitudinal follow-up studies should be encouraged to demonstrate its therapeutic usefulness in this area. In addition, more comparative studies should be conducted to compare the effectiveness of PDT with LED or laser therapy and with other therapeutic modalities for dysplastic OEL lesions.

References

1. Rakesh N, Clint JB, Reddy SS, Nagi R, Chauhan P, Sharma S, et al. Clinical evaluation of photodynamic therapy for the treatment of refractory oral Lichen planus-A case series. Photodiagnosis and photodynamic therapy. 2018;24:280-285.

2. Soliman M, Kharbotly AE, Saafan A. Management of oral lichen planus using diode laser (980 nm): a clinical study. Egyptian Dermatology online journal. 2015;1:3.

3. De Oliveira AB, Ferrisse TM, Marques RS, de Annunzio SR, Brighenti FL, Fontana CR. Effect of photodynamic therapy on microorganisms responsible for dental caries: a systematic review and meta-analysis. International journal of molecular sciences. 2019;20:3585. 4. Chen HM, Cheng SJ, Chiang CP. Topical photodynamic therapy is the first-line treatment of choice for oral erythroleukoplakia and oral verrucous hyperplasia. J Formos Med Assoc. 2015;114:567-568.

5. Romeo U, Russo N, Palaia G, Tenore G, Del Vecchio A. Oral proliferative verrucous leukoplakia treated with the photodynamic therapy: a case report. Annali di stomatologia. 2014;5:77.

6. Akram Z, Javed F, Hosein M, Al-Qahtani MA, Alshehri F, Alzahrani AI, Vohra F. Photodynamic therapy in the treatment of symptomatic oral lichen planus: a systematic review. Photodermatology, photoimmunology & photomedicine. 2018;34:167-174.

7. Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clinics in dermatology. 2016;24:16-25.

8. Chen HM, Yu CH, Tsai T, Hsu YC, Kuo RC, Chiang CP. Topical 5-aminolevulinic acid-mediated photodynamic therapy for oral verrucous hyperplasia, oral leukoplakia and oral erythroleukoplakia. Photodiagnosis and photodynamic therapy. 2007;4:44-52.

9. Chen HM, Yu CH, Lin HP, Cheng SJ, Chiang CP. 5-Aminolevulinic acid-mediated photodynamic therapy for oral cancers and precancers. Journal of Dental Sciences. 2012;7:307-315.

10. Di Stasio D, Romano A, Russo D, Fiori F, Laino L, Caponio VCA, et al. Photodynamic therapy using topical toluidine blue for the treatment of oral leukoplakia: A prospective case series. Photodiagnosis and Photodynamic Therapy. 2020;31:101888.

11. Shafirstein G, Friedman A, Siegel E, Moreno M, Bäumler W, Fan CY, et al. Using 5-aminolevulinic acid and pulsed dye laser for photodynamic treatment of oral leukoplakia. Archives of Otolaryngology-Head & Neck Surgery. 2011;137:1117-1123.

12. Maloth KN, Velpula N, Kodangal S, Sangmesh M, Vellamchetla K, Ugrappa S, et al. Photodynamic therapy-a non-invasive treatment modality for precancerous lesions. Journal of lasers in medical sciences. 2016;7:30.

13. Lavaee F, Shadmanpour M. Comparison of the effect of photodynamic therapy and topical corticosteroid on oral lichen planus lesions. Oral diseases. 2019;25:1954-1963.

14. Levy JG, Obochi M. New applications in photodynamic therapy. Introduction. Photochemistry and photobiology. 1996;64:737-739.

15. Lin HP, Chen HM, Yu CH, Yang H, Wang YP, Chiang CP. Topical photodynamic therapy is very effective for oral verrucous hyperplasia and oral erythroleukoplakia. Journal of oral pathology & medicine. 2010;39:624-630.

16. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, Djavid GE, Fateh M, Beitollahi JM. Methylene blue-mediated photodynamic therapy: A possible alternative treatment for oral lichen planus. Lasers in Surgery

and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery. 2006;38:33-38.

17. Mirza S, Rehman N, Alrahlah A, Vohra F. Efficacy of photodynamic therapy or low level laser therapy against steroid therapy in the treatment of erosive-atrophic oral lichen planus. Photodiagnosis and photodynamic therapy. 2018;21:404-408.

18. Konopka KRYSTYNA, Goslinski TOMASZ. Photodynamic therapy in dentistry. Journal of dental research. 2007;86:694-707.

19. Ch SK. Photo dynamic therapy in oral diseases. Int J Biol Med Res. 2012;3:1875-1883.

20. Stájer A, Kajári S, Gajdács M, Musah-Eroje A, Baráth Z. Utility of photodynamic therapy in dentistry: Current concepts. Dentistry journal. 2020;8:43.

21. Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B. 2009;96:1-8.

22. Romano A, Di Stasio D, Gentile E, Petruzzi M, Serpico R, Lucchese A. The potential role of Photodynamic therapy in oral premalignant and malignant lesions: A systematic review. Journal of Oral Pathology & Medicine. 2021;50;333-344.

23. Sadaksharam J, Nayaki KT, Panneer Selvam N. Treatment of oral lichen planus with methylene blue mediated photodynamic therapy-a clinical study. Photodermatology, photoimmunology & photomedicine. 2012;28:97-101.

24. Sieroń A, Adamek M, Kawczyk-Krupka A, Mazur S, Ilewicz L. Photodynamic therapy (PDT) using topically applied δ -aminolevulinic acid (ALA) for the treatment of oral leukoplakia. Journal of oral pathology & medicine. 2003;32:330-336.

25. Yu CH, Chen HM, Hung HY, Cheng SJ, Tsai T, Chiang CP. Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion. Oral oncology. 2008;44:595-600.

26. Yu CH, Lin HP, Chen HM, Yang H, Wang YP, Chiang CP. Comparison of clinical outcomes of oral erythroleukoplakia treated with photodynamic therapy using either light-emitting diode or laser light. Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery. 2009;41:628-633.

27. Vohra F, Al-Kheraif AA, Qadri T, Hassan MIA, Ahmed A, Warnakulasuriya S, et al. Efficacy of photodynamic therapy in the management of oral premalignant lesions. A systematic review. Photodiagnosis and photodynamic therapy 2015;12:150-159.

28. Sharma S, Rakesh N, Sharma S, Iqbal Z. Erosive lichen planus treated with photodynamic therapy: A case report and review of literature. J Adv Oncol. 2017;1003.

29. Gold MH. Introduction to photodynamic therapy: early experience. Dermatologic clinics. 2017;25:1-4.

30. Allison RR, Moghissi K. Photodynamic therapy (PDT): PDT mechanisms. Clinical endoscopy. 2013;46:24.

31. Kvaal SI, Angell-Petersen E, Warloe T. Photodynamic treatment of oral lichen planus. Oral surgery, oral medicine, oral pathology and oral radiology. 2013;115:62-70.

32. Malik R, Manocha A, Suresh DK. Photodynamic Therapy - A Strategic Review: Indian J Dent Res. 2010;21:285-91.

Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky K.
 Aminolevulinic Acid-Based Photodynamic Therapy: Clinical Research and Future Challenges. Cancer. 1997;79:2282-308.

Conflict of interest

Non declared.